JG
PSTV

Jefferies Group’s Plus Therapeutics PSTV Stock Holding History

Jefferies Group’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4
Closed -$214K – 2603
2018
Q1 		$214K Buy
+4
New +$263K ﹤0.01% 1940
2015
Q1 		– Hold
0
– -$5K – 2330
2014
Q4 		– Hold
0
– – – 1880

Other funds holding PSTV

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Jefferies Group's PSTV Position: Q2 2018 in Review

Jefferies Group sold out of Plus Therapeutics (PSTV) in Q2 2018, closing a stake of 4 shares — an estimated $214K sold.

Jefferies Group first reported a position in PSTV in Q1 2018 and held it in 1 quarter. The position peaked at $214K in Q1 2018. 8 funds tracked by Wall St. Rank hold PSTV as of Q2 2018.

  • Jefferies Group reported no remaining Plus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Jefferies Group sold 4 Plus Therapeutics shares in Q2 2018, an estimated $214K.
  • Jefferies Group first reported a position in Plus Therapeutics in Q1 2018 and held it in 1 quarter.
  • Jefferies Group's Plus Therapeutics position peaked at $214K in Q1 2018.
  • 8 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2018.

Based on Jefferies Group's 13F filing for Q2 2018, filed 14 Aug 2018.